Business Wire

Creative Artists Agency Names Steve Hasker CEO of CAA Global

Del

Leading entertainment and sports agency, Creative Artists Agency (CAA), announced today that industry veteran Steve Hasker has been appointed CEO of the recently structured CAA Global. He will manage the intersection between CAA's market-leading representation business and its high-growth businesses and investments, bringing together the agency's growth platforms and ongoing strategic initiatives. He will also join CAA's board of directors, and oversee the company's strategic planning, mergers and acquisitions, principal investing, and corporate development initiatives, as well as the company's data strategy.

Hasker most recently served as Global President and Chief Operating Officer of Nielsen Holdings PLC, where he oversaw all of Nielsen’s commercial, data, and product-related activities for both the media and consumer businesses. He joins CAA in January, 2018.

“CAA Global is an exciting step in the continued growth and diversification of CAA,” said agency President Richard Lovett. “Steve is a transformational and highly accomplished industry executive, and we are thrilled, after conducting an extensive search, to have found someone who also shares so profoundly our cultural priority of collaborative success. Under Steve’s leadership, we are confident that CAA Global will capitalize on the strength of CAA’s position at the nexus of talent, content, technology, and brands across the global marketplace to accelerate growth and innovation for CAA and our clients.”

CAA Global includes assets such as CAA China, a joint venture with CMC Capital Partners that builds upon CAA’s 12 years of success in the fast-growing market; Evolution Media, CAA’s merchant bank, founded in 2008, that has advised on billions of dollars in mergers and acquisitions and manages a $500 million media, technology and consumer brand investment vehicle; CAA Ventures, an early-stage venture capital fund with 45 portfolio companies; and Vancouver-based Creative Labs, which builds consumer-facing technology companies and next-generation media and entertainment experiences.

“CAA is very well positioned to take advantage of massive technology disruption and changing consumer behavior,” said Hasker. “I look forward to building upon CAA’s long history of industry leadership and relentless innovation to create successful new global businesses and opportunities for its clients and the company.”

CAA has long been recognized for its unmatched roster of the world’s premier artists, athletes, and blue-chip brands, as well as its category leadership in packaging television and film content and live experiences. CAA was also the first agency to build a sports business, create an investment bank, launch a venture fund, found technology start-up companies, establish a presence in China, and start a successful private equity vehicle, among other industry advances.

“CAA’s management team has demonstrated its ability to help drive the evolution of the media and entertainment industry. Since our initial investment in CAA, the company has continued to expand and diversify to capture its enormous potential,” said James Coulter, co-founder of global investment firm TPG, CAA’s majority shareholder. “CAA Global exemplifies these successful efforts, and with Steve as its CEO, we have a deeply experienced business leader with a proven ability to drive growth. We’re confident CAA will continue to accomplish exciting things.”

Prior to joining Nielsen in 2009, Hasker served as a partner in McKinsey & Company’s Global Media, Entertainment and Information practice, focused on strategy, growth, and innovation in television, data, filmed entertainment, sports, and digital advertising. Before joining McKinsey, Hasker served in a number of financial roles in the U.S., Russia and Australia.

A lecturer at Columbia University and New York University, Hasker’s research has been published in the Harvard Business Review. He graduated from the University of Melbourne and earned his MBA and Masters in International Affairs, both with honors, from Columbia University.

About Creative Artists Agency

Leading entertainment and sports agency Creative Artists Agency (CAA) represents many of the most successful professionals working in film, television, music, theatre, video games, sports, and digital content, and provides a range of strategic marketing and consulting services to corporate clients. CAA is a leader in sports, representing more than 1,000 of the world’s top athletes in football, baseball, basketball, hockey, soccer, tennis, and golf, and works in the areas of broadcast rights, corporate marketing initiatives, licensing, and sports properties for sales and sponsorship opportunities.

Contact information

Creative Artists Agency (CAA)
Beth McClinton, 424.288.2247
Beth.McClinton@caa.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Heidelberg Engineering Announces the CE-Marking of ANTERION21.9.2018 16:41Pressemelding

Heidelberg Engineering, the leader in diagnostic imaging known for the internationally-acclaimed SPECTRALIS ® retina and glaucoma platform, announces the CE-marking of ANTERION ® – an innovative platform designed to transform anterior segment diagnostics and workflow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005442/en/ The new Heidelberg Engineering ANTERION® provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. (Graphic: Business Wire) The new ANTERION provides the most important anterior segment examinations and measurements in one modular, upgradeable platform. It is a single, workflow-efficient solution that brings together corneal topography and tomography, anterior segment metrics, axial length measurement and IOL calculation to transform the day-to-day routine of busy practices and clinics. Heidelberg Engineering has leveraged its core OCT technolo

Florian Winterstein Becomes New CEO of Jedox21.9.2018 15:46Pressemelding

The supervisory board of Jedox AG, a leading vendor of business intelligence and enterprise planning software, has appointed Florian Winterstein as Chief Executive Officer (CEO) effective October 2, 2018. This nomination will support Jedox’s international growth and a new development phase initiated by its latest fund raising in April 2018 with Iris Capital, eCAPITAL entrepreneurial Partners AG and Wecken & Cie. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180921005416/en/ Florian Winterstein (Photo: Business Wire) With 25 years of experience in strategy consulting and leadership in software and service organizations, Winterstein brings to the company a valuable combination of expertise in cloud solutions, business development, and value creation for customers and partners. As former Chief Strategy Officer of BravoSolution, he positioned the software-as-a-service company as trendsetting digitalization partner, extending it

Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib) for the Treatment of ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib21.9.2018 13:30Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the full approval of ALUNBRIG® (brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. ALUNBRIG is a tyrosine kinase inhibitor (TKI) designed to target and inhibit the ALK mutation in NSCLC. Approximately three to five percent of NSCLC patients globally have the ALK mutation. If the CHMP opinion is affirmed, and the European Commission approves ALUNBRIG, it will become the only ALK inhibitor available in the European Union as a one tablet per day dose that can be taken with or without food. The randomized, global Phase 2 ALTA trial was designed to investigate the efficacy and safety of ALUNBRIG in patients with locally advanced or metastatic ALK+

Asda Selects HCL Technologies to Help Drive IT Transformation21.9.2018 12:16Pressemelding

HCL Technologies (HCL), a leading global technology company, today announced that it has been selected to help drive IT transformation at the UK’s third-largest grocery retailer, Asda. The three-year application services contract will see HCL transform Asda’s IT Application Services with a new DevOps delivery model to drive data and analytics and support back-office applications through the full lifecycle of development, testing and support. HCL will also build a central data management platform to enable Asda to improve its insight and analytics capabilities. Asda operates more than 600 stores across the UK, employing over 135,000 people. Asda wanted to adopt a more agile approach towards application development and testing. This would allow the company to respond faster to business requirements and reduce time to market, while driving better user experience and satisfaction. HCL was selected due to its extensive expertise in successfully delivering similar large scale IT transformati

Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)21.9.2018 05:30Pressemelding

Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), provided a positive opinion for Cabometyx® (cabozantinib) as a monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have been previously treated with sorafenib. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). Alexandre Lebeaut, MD, Executive Vice President, R&D and Chief Scientific Officer, Ipsen, said: “The global burden of liver cancer is increasing and despite the recent introduction of new agents, it remains the second leading cause of cancer mortality worldwide. Following today’s positive CHMP opinion and if approved by the European Commission, Cabometyx ® as monotherapy will give patients with HCC a much-needed new oral therapeutic option.” Dr Lorenza Rimassa,

Quanergy Selected as Exclusive LiDAR Partner for VRCO21.9.2018 05:00Pressemelding

Quanergy Systems, Inc., a global leader in the design and development of solid state LiDAR sensors and smart sensing solutions, and VRCO, designer and manufacturer of the luxury high-end e-VTOL (electric Vertical Take-Off and Landing) craft, the NeoXcraft XP2, today announced that VRCO will exclusively use Quanergy’s S3 solid state LiDAR sensors in the testing and market release versions of the aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180920006036/en/ VRCO NeoXcraft XP2 with Quanergy S3 LiDAR Sensor (Graphic: Business Wire) The NeoXcraft XP2, which VRCO and the University of Derby unveiled in late 2017 and intend to launch in 2020, is a two-passenger e-VTOL high-speed land, air, and water capable craft. The craft can scan and memorize take-off locations and store the data for use on the next approach to the same location. Quanergy’s innovative S3 solid state LiDAR sensor will be used for downward and forward